Free Trial
TSE:CRDL

Cardiol Therapeutics (CRDL) Stock Price, News & Analysis

C$3.31
+0.09 (+2.80%)
(As of 05/27/2024 ET)
Today's Range
C$3.19
C$3.35
50-Day Range
C$1.98
C$3.31
52-Week Range
C$0.89
C$3.35
Volume
118,084 shs
Average Volume
136,177 shs
Market Capitalization
C$228.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CRDL stock logo

About Cardiol Therapeutics Stock (TSE:CRDL)

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

CRDL Stock Price History

CRDL Stock News Headlines

CRDL:CA Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc Class A
CRDL.TO - Cardiol Therapeutics Inc.
See More Headlines
Receive CRDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
C$-30,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$3.37 per share
Book Value
C$0.30 per share

Miscellaneous

Free Float
N/A
Market Cap
C$228.39 million
Optionable
Not Optionable
Beta
0.68
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. David G. Elsley MBA
    President, CEO & Director
  • Mr. Christopher J. Waddick C.A.
    C.M.A., CPA, CMA, MBA, CFO, Corporate Secretary & Director
  • Mr. Bernard Lim B.Sc.
    Chief Operating Officer
  • Dr. Andrew Warwick Hamer M.D. (Age 62)
    Chief Medical Officer & Head of Research & Development
    Comp: $746.56k
  • Trevor Burns
    Investor Relations

CRDL Stock Analysis - Frequently Asked Questions

Should I buy or sell Cardiol Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRDL shares.
View CRDL analyst ratings
or view top-rated stocks.

How have CRDL shares performed in 2024?

Cardiol Therapeutics' stock was trading at C$1.10 at the beginning of the year. Since then, CRDL stock has increased by 200.9% and is now trading at C$3.31.
View the best growth stocks for 2024 here
.

How do I buy shares of Cardiol Therapeutics?

Shares of CRDL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:CRDL) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners